Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized adjuvant trial in resected mucosal melanoma
ChiCTR-TRC-11001798Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2007
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in mucosal melanoma (MM) comparing Observation, High-dose interferon alfa-2b and Temozolomide + cisplatin (3 arms). Primary endpoint: Relapse-free survival. Started Jan 2007; status: completed.
02
Drugs
temozolomidecisplatininterferon alfa-2b
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on ChiCTR-TRC-11001798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001798.